Morphosys to receive milestone payment from Centocor Ortho
This article was originally published in Scrip
Executive Summary
Centocor Ortho Biotech is to shell out a milestone payment to Morphosys, having initiated a Phase I clinical trial using the German company's HuCAL-derived, fully human antibody in inflammation.